American Oriental Bioengineering Considering Several Acquisition Targets [View article]
I was surprised to see AOB drop 10% on it's annual report and conference call yesterday. As an AOB shareholder for just over 3 years now, I still see a bright future for the company with organic growth of 30% and plenty of cash for acquisitions. I also believe LTUS (Lotus Pharmaceuticals) is worth a look here, as the company has plans for a nasdaq listing, and is currently trading at a PE of 3 based on 2008 make good target of .28/share, with over 60% income growth yoy.
-
I was surprised to see AOB drop 10% on it's annual report and conference call yesterday. As an AOB shareholder for just over 3 years now, I still see a bright future for the company with organic growth of 30% and plenty of cash for acquisitions.
Mar 07 07:44 am
|Rating:
0
0
All Comments by ChinaMart »American Oriental Bioengineering Considering Several Acquisition Targets [View article]
I also believe LTUS (Lotus Pharmaceuticals) is worth a look here, as the company has plans for a nasdaq listing, and is currently trading at a PE of 3 based on 2008 make good target of .28/share, with over 60% income growth yoy.